Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.57 |
| ▸ | CNR1 | P21554 | 7/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10991207 | 0.88 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL10989639 | 0.88 | CNR2 (0.47) | CNR2CNR1TSHRKDM4EALDH1A1 | |
| SCHEMBL10998292 | 0.87 | CNR2 (0.46) | CNR2CNR1TSHRKDM4EALDH1A1 | |
| SCHEMBL10992081 | 0.87 | CNR2 (0.50) | CNR2CNR1TSHRKDM4EALDH1A1 | |
| SCHEMBL11160417 | 0.86 | ACMSD (0.49) | CNR2CNR1TSHRKDM4EALDH1A1 | |
| SCHEMBL10993811 | 0.86 | CNR2 (0.50) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL10990937 | 0.86 | MCL1 (0.48) | CNR2CNR1TSHRKDM4EALDH1A1 | |
| SCHEMBL858856 | 0.86 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL11372017 | 0.85 | CNR2 (0.45) | CNR2CNR1TSHRKDM4EALDH1A1 | |
| SCHEMBL10994806 | 0.85 | CYP3A4 (0.46) | CNR2KDM4EALDH1A1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4853225-A | Process for implanting a medicament depot | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-08-01 | — | — | US | claimed |
| EP-0003144-B1 | 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION, THEIR APPLICATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-08-05 | — | — | EP | claimed |
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE (FR) | 2012-06-14 | — | — | US | disclosed |
| EP-2432763-A1 | 1,4 DIHYDROPYRIDINE DERIVATIVES AND THEIR USES | Université de Lille 2 Droit et Santé (FR) | 2012-03-28 | — | — | EP | disclosed |
| EP-2261211-A1 | 1,4-dihydropyridine derivatives and their uses | Université de Lille 2 Droit et Santé (FR) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010133973-A1 | 1,4 DIHYDROPYRIDINE DERIVATIVES AND THEIR USES | UNIVERSITE LILLE 2 DROIT ET SANTE (FR) | 2010-11-25 | — | — | WO | disclosed |
| US-4853225-A | Process for implanting a medicament depot | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-08-01 | — | — | US | disclosed |
| US-4549022-A | ANTIBACTERIAL AGENT; STIMULANT ON CENTRAL NERVOUS SYSTEM | HOFFMANN-LA ROCHE INC. (US) | 1985-10-22 | — | — | US | disclosed |
| US-4521535-A | ANTIBACTERIAL AGENTS; STIMULANTS FOR CENTRAL NERVOUS SYSTEM | HOFFMANN-LA ROCHE INC. (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0003144-B1 | 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION, THEIR APPLICATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-08-05 | — | — | EP | disclosed |
| EP-0003144-A2 | 4-Pyridone-3-carboxylic acid derivatives, pharmaceutical compositions containing them, processes for their preparation, their application | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885TSHR 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.